Anika Therapeutics (AKP) Stock Statistics & Valuation Metrics
Total Valuation
Anika Therapeutics has a market cap or net worth of EUR 250.68M. The enterprise value is EUR 187.52M.
- Market Cap
- EUR 250.68M
- Enterprise Value
- EUR 187.52M
Share Statistics
Anika Therapeutics has 13,382,966 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 13,382,966
- Owned by Insiders
- 5.00%
- Owned by Institutions
- 29.69%
Financial Efficiency
Anika Therapeutics’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is -6.48%.
- Return on Equity (ROE)
- -0.08
- Return on Assets (ROA)
- -0.06
- Return on Invested Capital (ROIC)
- -6.48%
- Return on Capital Employed (ROCE)
- -0.07
- Revenue Per Employee
- 480.08K
- Profits Per Employee
- -46.30K
- Employee Count
- 235
- Asset Turnover
- 0.59
- Inventory Turnover
- 2.61
Valuation Ratios
The current PE Ratio of Anika Therapeutics is -72.02. Anika Therapeutics’s PEG ratio is -0.25.
- PE Ratio
- -72.02
- PS Ratio
- 2.15
- PB Ratio
- 1.90
- Price to FCF
- 462.21
- Price to Operating Cash Flow
- 43.61
- PEG Ratio
- -0.25
Income Statement
In the last 12 months, Anika Therapeutics had revenue of 112.82M and earned -10.88M in profits. Earnings per share was -0.76.
- Revenue
- 112.82M
- Gross Profit
- 63.81M
- Operating Income
- -11.05M
- Pretax Income
- -9.31M
- Net Income
- -10.88M
- EBITDA
- -3.58M
- Earnings Per Share (EPS)
- -0.76
Cash Flow
In the last 12 months, operating cash flow was 5.98M and capital expenditures -5.42M, giving a free cash flow of 562.00K billion.
- Operating Cash Flow
- 5.98M
- Free Cash Flow
- 562.00K
- Free Cash Flow per Share
- 0.04
Dividends & Yields
Anika Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.22%
- Earnings Yield
- -1.45%
Stock Price Statistics
- Beta
- 0.66
- 52-Week Price Change
- 119.28%
- 50-Day Moving Average
- 17.33
- 200-Day Moving Average
- 13.49
- Relative Strength Index (RSI)
- 61.52
- Average Volume (3m)
- 54
Important Dates
Anika Therapeutics upcoming earnings date is Nov 06, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Jul 29, 2026
- Next Earnings Date
- Nov 06, 2026
- Ex-Dividend Date
- ―
Financial Position
Anika Therapeutics as a current ratio of 4.72, with Debt / Equity ratio of 18.30%
- Current Ratio
- 4.72
- Quick Ratio
- 3.86
- Debt to Market Cap
- 0.18
- Net Debt to EBITDA
- 8.73
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Anika Therapeutics has paid 672.00K in taxes.
- Income Tax
- 672.00K
- Effective Tax Rate
- -0.07
Enterprise Valuation
Anika Therapeutics EV to EBITDA ratio is 90.00, with an EV/FCF ratio of 435.60.
- EV to Sales
- 2.03
- EV to EBITDA
- 90.00
- EV to Free Cash Flow
- 435.60
- EV to Operating Cash Flow
- 40.96
Balance Sheet
Anika Therapeutics has EUR 38.41M in cash and marketable securities with EUR 23.32M in debt, giving a net cash position of EUR 15.10M billion.
- Cash & Marketable Securities
- EUR 38.41M
- Total Debt
- EUR 23.32M
- Net Cash
- EUR 15.10M
- Net Cash Per Share
- EUR 1.13
- Tangible Book Value Per Share
- EUR 9.52
Margins
Gross margin is 62.16%, with operating margin of -4.24%, and net profit margin of -3.14%.
- Gross Margin
- 62.16%
- Operating Margin
- -4.24%
- Pretax Margin
- -2.41%
- Net Profit Margin
- -3.14%
- EBITDA Margin
- 2.25%
- EBIT Margin
- -2.41%
Analyst Forecast
The average price target for Anika Therapeutics is EUR 20.54, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 20.54
- Price Target Upside
- 12.83% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- -9.02%
- EPS Growth Forecast
- 94.07%
Scores
- Smart Score
- 7
- AI Score
- ―
